11/09/2025
Desmoid tumor of the re**us abdominis muscle is a rare, benign (non-cancerous) but locally aggressive fibroblastic tumor that arises from the musculoaponeurotic structures, particularly in the abdominal wall.
-Nature: Benign, non-inflammatory fibroblastic tumor with a tendency for local invasion and recurrence after resection. It accounts for ~0.03% of all neoplasms and has an incidence of 3.7 cases per million per year.
-Demographics: More frequent in women (2:1 ratio), especially between ages 20–40. Often associated with pregnancy, postpartum periods, or hormonal factors like estrogen therapy.
Symptoms
-Presentation: Typically presents as a firm, palpable mass, which may be painless or painful, depending on size and location. Pain may increase as the tumor grows and compresses nearby structures like muscles or nerves.
Diagnosis
-Physical Exam: A firm, fixed mass in the abdominal wall, often in the re**us abdominis muscle.
Imaging:
-Ultrasound: Shows a hypoechoic, well-circumscribed mass with possible vascularity on Doppler.
-CT: Reveals a hypodense or isodense mass with mild enhancement after contrast administration. It may have well-defined or ill-defined margins.
-MRI: Preferred for assessing local tumor extension. Desmoids appear isointense to muscle on T1-weighted images and hyperintense with band-like low-signal areas on T2-weighted images.
Differential Diagnosis: Includes acute hematoma, fibrosarcoma, lymphoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, neurofibroma, endometriosis (especially post-cesarean), and metastases.
Treatment
-Observation: Stable, asymptomatic tumors can be monitored with imaging every 3–6 months ("wait-and-see" approach).
-Surgery: The mainstay for symptomatic or invasive abdominal wall desmoids. Complete resection with negative margins is preferred to reduce recurrence (up to 87% in younger patients). Reconstruction with polypropylene mesh or acellular dermal matrix may be needed for large defects to prevent herniation.
Non-Surgical Therapies:
-Radiation Therapy: Used for unresectable tumors or as adjuvant therapy, though less common for abdominal wall tumors.
-Systemic Therapy: Includes chemotherapy, hormonal therapy (e.g., tamoxifen due to estrogen sensitivity), or non-steroidal anti-inflammatory drugs (NSAIDs). Molecular targeted agents are also emerging.
Challenges: High recurrence rates (over 30% in some cases) and difficulty achieving margin-free resection due to local invasion.
Prognosis
-Desmoid tumors do not metastasize but can cause significant morbidity due to local invasion and recurrence.
Recurrence is more likely if surgical margins are positive.